Detection of Burkholderia pseudomallei O-antigen serotypes in near-neighbor speciesReportar como inadecuado




Detection of Burkholderia pseudomallei O-antigen serotypes in near-neighbor species - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Microbiology

, 12:250

Microbial genetics, genomics and proteomics

Abstract

BackgroundBurkholderia pseudomallei is the etiological agent of melioidosis and a CDC category B select agent with no available effective vaccine.
Previous immunizations in mice have utilized the lipopolysaccharide LPS as a potential vaccine target because it is known as one of the most important antigenic epitopes in B.
pseudomallei.
Complicating this strategy are the four different B.
pseudomallei LPS O-antigen types: A, B, B2, and rough.
Sero-crossreactivity is common among O-antigens of Burkholderia species.
Here, we identified the presence of multiple B.
pseudomallei O-antigen types and sero-crossreactivity in its near-neighbor species.

ResultsPCR screening of O-antigen biosynthesis genes, phenotypic characterization using SDS-PAGE, and immunoblot analysis showed that majority of B.
mallei and B.
thailandensis strains contained the typical O-antigen type A.
In contrast, most of B.
ubonensis and B.
thailandensis-like strains expressed the atypical O-antigen types B and B2, respectively.
Most B.
oklahomensis strains expressed a distinct and non-seroreactive O-antigen type, except strain E0147 which expressed O-antigen type A.
O-antigen type B2 was also detected in B.
thailandensis 82172, B.
ubonensis MSMB108, and Burkholderia sp.
MSMB175.
Interestingly, B.
thailandensis-like MSMB43 contained a novel serotype B positive O-antigen.

ConclusionsThis study expands the number of species which express B.
pseudomallei O-antigen types.
Further work is required to elucidate the full structures and how closely these are to the B.
pseudomallei O-antigens, which will ultimately determine the efficacy of the near-neighbor B serotypes for vaccine development.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2180-12-250 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: JoshuaKStone - MarkMayo - StephanieAGrasso - JenniferLGinther - StephanieDWarrington - ChristopherJAllender - AdinaDoyle - Shalama

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados